文献速递消化道肿瘤放疗胸部肿瘤放疗

食管癌新辅助放化疗后肺受照剂量与预后相关

Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy.
PubMed 文献 · Radiat Oncol · 2019-05-24

本研究回顾性分析123例接受新辅助放化疗联合手术(三联治疗)的食管癌患者,评估肺和心脏受照剂量体积与预后的关系。多因素分析显示肺V20和V5与总生存独立相关,而平均心脏剂量与生存无关。肺V20≤23%与>23%患者的5年OS分别为54.4%与5%。

要点

  • 肺V20和V5是食管癌三联治疗总生存的独立预测因素。
  • 肺V20≤23%患者5年OS显著优于>23%者(54.4% vs 5%)。
  • 平均心脏剂量与生存 outcomes 无显著关联。

核心结论

  • 肺受照剂量与接受新辅助放化疗联合手术的食管癌患者生存结局独立相关。

研究设计与样本

  • 回顾性队列研究,纳入两家三级机构2010至2015年间接受三联治疗的123例食管癌患者。
  • 采用Cox回归模型识别总生存预测因素,并用ROC曲线选取剂量体积截断值。

主要发现

  • 中位随访28.3个月(范围4.7-92.8个月),中位OS为34.0个月(95%CI 27.4-40.6个月),中位PFS为24.8个月(95%CI 18.9-30.7个月)。
  • 多因素分析调整手术切缘和病理治疗反应后,肺V20(HR 1.09,95%CI 1.04-1.14,p<0.001)和肺V5(HR 1.02,95%CI 1.00-1.05,p=0.03)与OS相关。
  • 肺V20≤23% vs >23%的5年OS为54.4% vs 5%(p<0.001);肺V5≤56% vs >56%的5年OS为81.5% vs 23.4%(p<0.001)。
  • 平均心脏剂量与生存结局无关联。

关键数值与推荐

  • 肺V20截断值为23%,肺V5截断值为56%,基于ROC曲线选取。

临床怎么用

  • 在食管癌新辅助放化疗计划设计时,应关注肺V20和V5,尽量将肺V20控制在23%以下、肺V5控制在56%以下以改善生存。

局限性

  • 回顾性研究,样本量有限,截断值需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic significance of radiation dose to the lung or heart is unknown in esophageal cancer patients receiving neoadjuvant chemoradiotherapy followed by surgery (trimodal therapy). This study aimed to determine the association between lung and heart radiation dose volumes and prognosis of esophageal cancer after trimodal therapy. METHODS: This study reviewed 123 esophageal cancer patients treated with trimodal therapy in two tertiary institutions between 2010 and 2015. The dose-volume histogram parameter of Vx was defined as the percentage of total organ volume receiving a radiation dose of x (Gy) or more. Predictors of overall survival (OS) were identified using Cox regression models. Receiver-operating characteristic curves were used to select cut-off values for dose-volume. RESULTS: Median follow-up was 28.3 months (range: 4.7-92.8 months). Median OS and progression-free survival were 34.0 months (95% confidence interval [CI]: 27.4-40.6 months) and 24.8 months (95% CI, 18.9-30.7 months), respectively. Multivariate analyses showed that lung V20 (hazard ratio, 1.09; 95% CI: 1.04-1.14; p < 0.001) and lung V5 (hazard ratio, 1.02; 95% CI: 1.00-1.05; p = 0.03) were associated with OS when adjusting for surgical margin and pathological treatment response. The 5-year OS for patients with lung V20 ≤ 23% vs. patients with lung V20 > 23% was 54.4% vs. 5% (p < 0.001) whereas that for patients with lung V5 ≤ 56% vs. patients with lung V5 > 56% was 81.5% vs. 23.4% (p < 0.001). Mean heart dose showed no association with survival outcomes. CONCLUSIONS: Lung radiation dose was independently associated with survival outcomes in esophageal cancer patients treated with neoadjuvant chemoradiotherapy and surgery.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin JB, Hung LC, Cheng CY, et al. Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy. Radiat Oncol. 2019. PMID: 31126307. doi:10.1186/s13014-019-1283-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。